NCT06673043

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

Anifrolumab Real-world Treatment Outcomes in Polish Patients With Systemic Lupus Erythematosus (SLE). Multicenter, Non-interventional Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice.

Detailed description

This is multicenter, observational, cohort study designed to collect longitudinal data on the management and clinical outcomes of patients with SLE that received anifrolumab in the scope of routine clinical practice within the frames of National Drug Program (NDP) for up to 30 months (\~ 6 months baseline and \~24 months follow-up date).

Conditions

• Lupus Erythematosus, Systemic

Interventions

Type	Name	Description
DRUG	Anifrolumab	Anifrolumab 300 mg concentrate for solution for infusion

Timeline

• Start date: 2025-02-28
• Primary completion: 2028-06-30
• Completion: 2028-06-30
• First posted: 2024-11-04
• Last updated: 2026-04-13

Locations

11 sites across 1 country: Poland

Regulatory

• FDA-regulated drug study